top of page
AdobeStock_45830660.jpeg

Let Us Help You with Your IR Goals

Please reach out for more information.

We are always happy to discuss your investor relations needs.

Companies interested in learning more about Kendall IR's investor relations and capital markets advisory services can reach out to Carlo Tanzi, Ph.D., Principal and Founder, at ctanzi@kendallir.com.

Contact

About Kendall IR

About Kendall IR

What is Kendall IR?

Kendall IR is a boutique investor relations, strategic communications, and capital markets advisory firm that works exclusively with biotech companies. The firm was founded in 2018 to give biotech management teams a differentiated level of strategic advisory support, combining deep scientific fluency with hands-on capital markets execution. Its tagline captures the focus: From Biotech. For Biotech.

Rather than treating investor relations as a generic corporate function, Kendall IR approaches it as a discipline that sits at the intersection of science, corporate strategy, and the capital markets. The team helps clients translate complex platform biology, pipeline data, and development strategy into a clear investor narrative, and then delivers that narrative to the right audiences. The firm supports biotech companies at every stage, from private financings and IPO readiness through ongoing public-company investor relations, always with senior practitioners directly responsible for the work.

Where is Kendall IR located?

Kendall IR is based in Cambridge, MA, in the heart of one of the world's leading biotech hubs, and is deeply integrated into the Boston-area life sciences community. Being embedded in this ecosystem gives the firm direct proximity to the management teams, investors, bankers, and scientific talent that shape the sector.

While the firm is Cambridge-based, its reach extends well beyond Boston. Kendall IR maintains established relationships across Wall Street and the broader life sciences capital markets, and works with biotech clients wherever they are located, including international clients in China, Taiwan, and throughout Europe. The team engages regularly with specialist healthcare investors, generalist funds, sell-side analysts, and investment banks across the major financial centers, supporting clients through financings and investor events in person and remotely as each situation requires.

Does Kendall IR only work with biotech companies?

Kendall IR works exclusively within the life sciences, but that focus extends beyond therapeutics companies to the broader ecosystem that surrounds them. In addition to drug developers, the firm supports companies in adjacent areas such as diagnostics, life science tools and platforms, and biomanufacturing and services. What ties these together is a shared investor base and a common need for advisors who understand the underlying science.

This singular focus on life sciences is a defining feature of the firm: its team understands drug development, platform science, clinical strategy, and the specialized investors who follow the sector, so clients across therapeutics, diagnostics, tools, and manufacturing do not have to educate their advisors on the fundamentals.

What types of companies does Kendall IR work with?

Kendall IR supports both private and public biotech companies. For private companies, this includes IPO readiness, S-1 drafting support, bank selection, and pre-IPO investor awareness, helping teams prepare well before they approach the public markets. For public companies, it includes ongoing investor relations, data disclosure readiness, sell-side analyst management, Q&A development, and investor event support such as R&D Days and KOL calls.

The firm works with companies across a wide range of stages, from earlier-stage private financings through crossover rounds, IPOs, follow-ons, and established public issuers. Because the underlying investor questions evolve as a company matures, Kendall IR tailors its support to where a client sits in that lifecycle, whether the immediate priority is building a first institutional shareholder base, preparing for a pivotal data readout, or sustaining engagement with covering analysts and long-only investors over time.

What results does Kendall IR aim to deliver for clients?

Kendall IR focuses on outcomes that matter to biotech management teams: increased investor interest and appreciation of a company's value, successful fundraising, and a lower cost of capital. These results are pursued through sharper messaging, disciplined investor targeting, and sound capital markets judgment.

Concretely, that can mean a corporate narrative that resonates with the right investors, a shareholder base built to support the stock through clinical readouts and other milestones, and financings executed on favorable terms. The firm views these as connected rather than separate goals: a clear, credible investment thesis attracts higher-quality investors, a stronger shareholder base reduces volatility and supports valuation, and both make future capital raises easier and less dilutive. The objective throughout is durable, long-term value creation rather than short-term visibility.

Choosing a Biotech IR Partner

Choosing a Biotech IR Partner

When should a biotech company hire an investor relations firm?

At every stage of a biotech company's lifecycle, from early private financings through post-IPO follow-ons and PIPEs, there is meaningful IR work to be done. Investor relations is an ongoing discipline that builds the institutional relationships, narrative clarity, and market credibility that compound over time. A company that invests in its investor story early arrives at every financing with investors who already understand the science, trust the management team, and are prepared to participate on favorable terms.

Whether a company is preparing for its first institutional raise, approaching a crossover round, or managing the demands of being public, engaging an IR partner sooner rather than later pays off. Kendall IR offers different scopes of engagement for companies at different stages, including more limited engagements for earlier-stage private companies, scaling from focused thought partnership at key milestones to a part-time acting IR function.

How do you choose the right investor relations firm for a biotech company?

The most important factors are sector-specific expertise, senior-level attention, and a demonstrated track record with companies at your stage. A firm that works exclusively in biotech will understand the science, the regulatory environment, and the investors who follow the sector without needing to be educated on the fundamentals.

It is also worth asking whether the firm can function as a genuine strategic thought partner or whether it operates primarily as an execution vendor. The most valuable IR counsel often comes at moments when the conventional wisdom is wrong, such as when a data readout calls for a counter-intuitive communication approach. Evaluate scientific fluency, capital markets depth, and the seniority of the people who will actually do the work, and confirm that the team who pitches you is the team who serves you. Ask for references and speak with CFOs from comparable companies. The Kendall IR team includes former heads of IR at public biotech companies, professionals with investment banking and capital markets backgrounds, and PhDs in molecular and cellular biology, a combination built to serve as a thought partner rather than a service provider.

What makes biotech investor relations different from traditional investor relations?

Biotech IR requires a combination of scientific fluency and capital markets expertise that most generalist IR firms do not have. The investors a biotech company is trying to reach are evaluating binary clinical outcomes, regulatory risk, and complex data. Communications need to translate that science into a clear, differentiated investment thesis without oversimplifying it, and to do so in the language that specialist healthcare funds, generalist crossover investors, and sell-side analysts each respond to differently.

Biotech IR is not a generic communications function. It sits at the intersection of science, corporate strategy, and the capital markets, and it requires practitioners who are genuinely fluent in all three. That intersection is precisely where Kendall IR operates.

How is Kendall IR different from other IR firms?

Several things set Kendall IR apart:
 

  • Biotech specialization: the firm works only in biotech, so its scientific and clinical fluency is built in rather than borrowed, and clients do not have to educate their advisors on the underlying science.

  • Senior-led execution: accomplished account leads with biotech and capital markets expertise are directly responsible for execution and delivery, not just oversight, so the people who set the strategy are also the ones doing the work.

  • Strategic thought partnership: Kendall IR operates as a strategic partner with a proactive, ownership mindset rather than a vendor executing tasks.

  • Independent thinking: the firm forms its own views and does not simply follow the herd, giving clients candid counsel rather than consensus advice.
     

Taken together, these qualities mean clients get a senior, science-literate partner who is genuinely invested in the outcome and willing to offer a considered, independent point of view.

Services and Approach

Services and Approach

What services does Kendall IR offer?

Kendall IR provides end-to-end investor relations and capital markets advisory support across three core areas:
 

  • Messaging and delivery: developing impactful communications materials that highlight a company's path to value creation, including the corporate presentation, IR webpage content, Q&A materials, conference call remarks, and press releases.

  • Investor targeting: building a thoughtful investor engagement strategy that reaches the right investors for a given company, matched to its stage, therapeutic area, modality, and development phase.

  • Capital markets advisory: supporting fundraising and strategic transactions, including bank and analyst selection, syndicate structure and economics, and investor conference prioritization.
     

In practice, engagements often combine all three, from developing a differentiated investment thesis and refining the corporate deck to preparing Q&A materials, running rehearsals for investor interactions, building a corporate communications calendar, and providing content and operational support for events such as R&D Days and KOL calls. A full overview of the firm's offerings is available on the Kendall IR Services page.

What is Kendall IR's approach to investor relations?

Kendall IR follows a four-part approach:
 

  • Knowledge: rapidly understand the client's technology, corporate strategy, and communication objectives.

  • Thought partnership: partner with the client to define the investor strategy and the story they want to tell.

  • Execute: create a customized investor message and help deliver it to the right target audience.

  • Optimize: test for investor perceptions and continuously refine communication goals over time.
     

Kendall IR is flexible in how it structures client arrangements, scaling the engagement to each client's specific needs and budget rather than applying a one-size-fits-all model. Some clients want thought partnership at key inflection points, while others want a firm that functions as a part-time acting IR function. In either case, the four-step approach keeps the work anchored to the client's strategy and the perceptions of its target investors.

What does a Kendall IR engagement look like?

Engagements are scaled to a client's needs and budget, ranging from more limited advisory support to full strategic and execution support that functions like a part-time acting Investor Relations Officer.

A lighter engagement might include thought partnership on IR strategy and messaging, feedback on the corporate presentation, and review of press releases. A fuller engagement can add in-depth editing of the corporate deck, Q&A development and rehearsal, drafting of press releases and conference call scripts, a corporate communications calendar, investor event support, external representation to investors, and a detailed investor outreach plan.

Most engagements evolve over time, expanding around milestones such as a financing, a major data readout, or an investor event, and scaling back during quieter periods. The specific mix of activities is defined jointly with each client at the outset and revisited as priorities shift. A fuller breakdown of what an engagement can include is available on the Kendall IR Services page.

What is an investment thesis and why does it matter?

A compelling investment thesis is a concise summary of the investment opportunity that serves as the foundation for all of a company's communication materials. Kendall IR helps clients build a thesis that typically conveys a differentiated platform with broad potential, an opportunity to transform the standard of care, a credible and competent management team, a substantial commercial opportunity, and near-term value-creating corporate milestones. This thesis then flows consistently through the corporate presentation, IR webpage, Q&A, conference call remarks, press releases, and investor outreach.

For a deeper discussion of why the investment thesis should come first, see the Kendall IR Insights article Start with a Compelling Investor Thesis.

How does Kendall IR approach investor targeting?

Kendall IR builds tailored investor targeting strategies rather than generic outreach lists. Targeting is matched to a company's profile across several dimensions, including company maturity and stage of financing, drug development stage, therapeutic area, and treatment modality.

The firm also weighs additional factors such as fund size and capacity, recent investment activity, peer company ownership from comparable analysis, and existing relationships. Target investor types span specialist healthcare funds, mutual funds, and earlier-stage venture investors. The Kendall IR team brings extensive capital markets experience to this work, including direct investment banking experience, which informs how it identifies and prioritizes the right investors for each client.

How do investor relations and public relations work together in biotech?

IR and PR serve distinct but complementary functions. Investor relations focuses on communicating with the capital markets, including institutional investors, equity research analysts, and investment banks, with the goal of building credibility, attracting high-quality shareholders, and supporting the company's cost of capital. Public relations focuses on broader stakeholder communications, including media, patients, partners, and the scientific community.

In biotech, the two functions are most closely aligned around major corporate events such as clinical data readouts, financing announcements, partnership disclosures, and IPOs, where the same news needs to reach financial and non-financial audiences simultaneously in ways that are consistent but calibrated to each. Kendall IR frequently works in partnership with PR firms and internal PR teams to coordinate these communications, ensuring the investor message and the broader public message reinforce one another.

Capital Markets and Fundraising

Capital Markets and Fundraising

How does Kendall IR support biotech IPOs?

Kendall IR provides comprehensive support for private biotech companies preparing to go public, including:
 

  • Reviewing and editing the corporate roadshow deck and developing the overarching investment thesis.

  • Developing and refining Q&A materials and running rehearsals for investor interactions.

  • Supporting S-1 drafting and disclosure aligned with the broader investor narrative.

  • Advising on bank and analyst selection, syndicate structure, and economics.

  • Driving pre-IPO awareness through news flow, media outreach, and investor conference prioritization.

  • Conducting investor targeting in the months preceding the IPO, working both independently and alongside the banks.
     

For more on how the investor base a company builds during a financing shapes its stock for years afterward, see the Kendall IR Insights article Who Gets the Shares?.

What kinds of fundraising has Kendall IR supported?

Since the firm's founding, Kendall IR has supported over 50 public and private fundraises, representing more than $3 billion in capital raised. That experience spans the full range of biotech financing structures, including IPOs, follow-on offerings, PIPEs, deSPACs, private rounds, strategic partnerships, and acquisitions.

Across these transactions, the firm's support typically spans messaging optimization, investor targeting and outreach, and capital markets advisory. That means sharpening the investment thesis and corporate materials ahead of a raise, identifying and prioritizing the right prospective shareholders, and advising on bank and analyst selection as well as syndicate structure and economics. Having worked across so many financings and structures, the team brings pattern recognition that helps clients anticipate investor questions, time their news flow, and position each raise to build a durable, high-quality shareholder base.

Does Kendall IR help with sell-side analysts and banks?

Yes. Kendall IR advises clients on identifying and engaging investment banks and equity research analysts, supports planning and execution of bank-led non-deal roadshows, and helps manage relationships with covering analysts. For financings, the firm provides counsel on bank and analyst selection as well as syndicate structure and economics, and helps clients prioritize and obtain invitations to investor conferences that raise company visibility.

Because the team includes professionals with capital markets and investment banking backgrounds, this counsel is grounded in a practical understanding of how banks and analysts actually operate, from how syndicates are assembled to how research coverage is initiated and sustained. That perspective helps clients build productive, well-managed relationships across the sell side rather than approaching each interaction in isolation, and to think about analyst and banking relationships as long-term assets that support the company across multiple financings and milestones.

Artificial Intelligence

Artificial Intelligence

How does Kendall IR use artificial intelligence?

AI is an essential part of how we work. When used well, it makes analysis faster and more efficient, and helps us produce higher-quality materials for our clients. But AI is a tool, not a substitute for judgment or deep experience. An experienced IR professional with extensive industry and capital markets expertise drives the analysis, directs the work, interprets what the tools surface, and owns the final product. The technology accelerates the work; the judgment behind it and our experience with the specific AI tools we use is what make the work valuable.

What AI tools does Kendall IR use?

We use a range of tools depending on the task. Alongside widely adopted general-purpose assistants like Claude and ChatGPT, we rely on professional-grade platforms built for financial analysis and investor relations, including AlphaSense and IR Insight. Each serves a distinct purpose, and we select the right tool for the specific problem at hand. These platforms are highly sophisticated and evolve constantly, with new capabilities, models, and features arriving at a rapid pace. We invest significant, ongoing effort to maintain fluency across them so our clients benefit from what these tools can do at their current frontier, not what they could do a year ago.

What does AI actually help you do for clients?

A few examples of how we put these tools to work:

  • Messaging and comp analysis. We analyze the questions investors typically raise around a given drug class, clinical event, or catalyst, then use that to sharpen client messaging and prepare management for the questions ahead.

  • Investor targeting. We compare peer ownership across many fund types to identify the right investors to target, understand how similar companies are held, and build a data-driven outreach strategy.

  • Earnings call preparation. We rapidly analyze the questions analysts typically ask on earnings calls so we can better prepare management for what's coming and stress-test their answers in advance.

  • Peer call analysis. We review peer earnings calls and analyst Q&A to identify emerging themes across the sector, giving management an early read on where the conversation is heading.
     

Across all of these, the AI surfaces patterns and structures the data. Our team interprets what it means and decides how to act on it.

How does Kendall IR handle data security?

We take data security seriously and fully appreciate the significance of the information we often handle. Material non-public information, unannounced clinical data, and confidential corporate strategy pass through our work regularly, and we treat that responsibility accordingly. We are deliberate about what information goes into which tools, how client materials are handled, and how confidential and non-public information is protected at every stage. As a matter of practice, we keep material non-public information out of general-purpose AI tools. Discretion and confidentiality are foundational to the IR relationship, and our use of technology is governed by that standard.

Where can I learn more about your approach to AI?

For a deeper look at how we think about AI in biotech IR, see our article Using AI to Supercharge Biotech Investor Relations, which covers our approach to AI-assisted communications, competitive intelligence, and investor targeting in more detail.

Companies interested in learning more about Kendall IR's investor relations and capital markets advisory services can reach out to Carlo Tanzi, Ph.D., Principal and Founder, at ctanzi@kendallir.com.

bottom of page